GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Corix Bioscience Inc (GREY:CXBS) » Definitions » Current Ratio

Corix Bioscience (Corix Bioscience) Current Ratio : 5.10 (As of Sep. 2017)


View and export this data going back to 2008. Start your Free Trial

What is Corix Bioscience Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Corix Bioscience's current ratio for the quarter that ended in Sep. 2017 was 5.10.

Corix Bioscience has a current ratio of 5.10. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Corix Bioscience's Current Ratio or its related term are showing as below:

CXBS's Current Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.85
* Ranked among companies with meaningful Current Ratio only.

Corix Bioscience Current Ratio Historical Data

The historical data trend for Corix Bioscience's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corix Bioscience Current Ratio Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
Current Ratio
Get a 7-Day Free Trial - - 0.04 - 0.01

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.01 - 0.42 5.10

Competitive Comparison of Corix Bioscience's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corix Bioscience's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's Current Ratio distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's Current Ratio falls into.



Corix Bioscience Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Corix Bioscience's Current Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Current Ratio (A: Dec. 2016 )=Total Current Assets (A: Dec. 2016 )/Total Current Liabilities (A: Dec. 2016 )
=0.005/0.687
=0.01

Corix Bioscience's Current Ratio for the quarter that ended in Sep. 2017 is calculated as

Current Ratio (Q: Sep. 2017 )=Total Current Assets (Q: Sep. 2017 )/Total Current Liabilities (Q: Sep. 2017 )
=4.011/0.786
=5.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corix Bioscience  (GREY:CXBS) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Corix Bioscience Current Ratio Related Terms

Thank you for viewing the detailed overview of Corix Bioscience's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Corix Bioscience (Corix Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.

Corix Bioscience (Corix Bioscience) Headlines

No Headlines